Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 19;6(4):00317-2020.
doi: 10.1183/23120541.00317-2020. eCollection 2020 Oct.

European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights

James D Chalmers  1 , Charlotte Balavoine  2 , Paola F Castellotti  3 , Christian Hügel  4 , Annabelle Payet  5 , Dennis Wat  6 , Gernot Rohde  4
Affiliations
Review

European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights

James D Chalmers et al. ERJ Open Res. .

Abstract

Once overlooked, awareness of nontuberculous mycobacterial pulmonary disease (NTM-PD) is rapidly rising, in line with increasing prevalence worldwide. The European Respiratory Society (ERS) International Congress 2019, held in Madrid, Spain, provided a platform for invigorating discussions and exciting new research in the field. This article explores approaches being taken to combat NTM-PD with a focus not only on novel prevalence and risk factor data, but also on emerging antimicrobials and their routes of delivery, and other potential treatment options in early clinical development.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.D. Chalmers reports grants and personal fees from AstraZeneca and Boehringer Ingelheim, grants from Gilead Sciences, grants and personal fees from GlaxoSmithKline, grants from Grifols, grants and personal fees from Insmed, and personal fees from Chiesi, Novartis and Zambon, outside the submitted work. Conflict of interest: C. Balavoine has nothing to disclose. Conflict of interest: P.F. Castellotti has nothing to disclose. Conflict of interest: C. Hügel reports personal fees from Boehringer Ingelheim and PulmonX, and nonfinancial support from Mukoviszidose e.V., Gilead, Insmed and Novartis, outside the submitted work. Conflict of interest: A. Payet has nothing to disclose. Conflict of interest: D. Wat reports grants and personal fees from Chiesi and Insmed, and personal fees from GlaxoSmithKline, outside the submitted work. Conflict of interest: G. Rohde reports personal fees from Boehringer Ingelheim, Chiesi, Essex Pharma, GlaxoSmithKline, Grifols, Insmed, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Solvay and Vertex, outside the submitted work.

References

    1. FDA The voice of the patient. Non-tuberculous mycobacterial lung infection. Public meeting: October 15, 2015; Report date April 2016. www.fda.gov/media/96932/download Date last accessed: February 2020.
    1. Andréjak C, Thomsen VØ, Johansen IS, et al. . Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514–521. doi:10.1164/rccm.200905-0778OC - DOI - PubMed
    1. Ito Y, Hirai T, Maekawa K, et al. . Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 2012; 16: 408–414. doi:10.5588/ijtld.11.0148 - DOI - PubMed
    1. Novosad SA, Henkle E, Schafer S, et al. . Mortality after respiratory isolation of nontuberculous mycobacteria. A comparison of patients who did and did not meet disease criteria. Ann Am Thorac Soc 2017; 14: 1112–1119. - PMC - PubMed
    1. Marras TK, Campitelli MA, Lu H, et al. . Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001–2013. Emerging Infect Dis 2017; 23: 468–476. doi:10.3201/eid2303.161927 - DOI - PMC - PubMed

LinkOut - more resources